Clin J Pain. 2012 Feb 14. [Epub ahead of print](via Co-Cure)
Adverse Events Attributable to Nocebo
in Randomized Controlled Drug Trials
in Fibromyalgia Syndrome
and Painful Diabetic Peripheral Neuropathy:
Systematic Review.
Häuser W, Bartram C, Bartram-Wunn E, Tölle T.
Department of Internal Medicine I, Klinikum Saarbrücken, Saarbrücken
Department of Psychosomatic Medicine and Psychotherapy
Department of Neurology, Technische Universität München, München, Germany.
Abstract
OBJECTIVE:
The objectives of the study were to determine the impact of nocebo effects on adverse events (AEs) in drug trials in fibromyalgia syndrome (FMS) and painful diabetic peripheral neuropathy (DPN).
METHODS:
MEDLINE, CENTRAL, SCOPUS, and the databases of the U.S. National Institutes of Health and the Pharmaceutical Research and Manufacturers of America were searched until December 31, 2010.
Randomized controlled trials with a parallel design of any drug therapy compared with pharmacological placebo in patients with FMS and DPN were included.
Pooled estimates of nocebo effects (number of patients with at least 1 AE and dropping out due AEs) were calculated for placebo and true drug groups by a random effects model.
RESULTS:
Fifty-eight FMS (62 DPN) trials included a total of 5065 (5095) patients in placebo groups.
The quality of reporting the assessment strategy of AEs was poor in most trials. The pooled estimate of the event rate drop out rate due to AEs in placebo groups was
Nocebo effects accounted for 72.0% (44.9) of the drop outs in true drug groups in FMS (DPN).
- 9.6 [95% confidence control (CI): 8.6-10.7] in placebo and
- 16.3 (95% CI: 14.1-31.2) in true drug groups of FMS trials and was
- 5.8 (95% CI: 5.1-6.6) in placebo and
- 13.2 (95% CI: 10.7-16.2) in true drug groups of DPN trials.
DISCUSSION:
Nocebo effects substantially accounted for AEs in drug trials of FMS and DPN.
Standards to assess and report AEs should be defined by regulatory agencies. Strategies to minimize nocebo effects in both clinical trials and clinical practice should be developed.
Pages
▼
No comments:
Post a Comment
Comments are most welcome! But please:
- No SPAM whatsoever, no supplements, no pharmaceuticals, no herbs or any other advertisements
- Absolutely no quack-doctors pushing their quack-BS websites (and if you are a quack, I will call you out)
- Be critical if you want to, but try to be coherent
Comments are moderated, because I am tired of Gerwyn-V99-The-Idiot and his moronic sockpuppets, and tired of the story of the two dogs, but I will try to publish everything else.
If you are not Gerwyn (and want to tell me something other than the story of the two dogs), then relax and write something! :-)